Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29469519 | 1.00 | CHRNB2 (0.56) | CHRNB2CHRNA4ALDH1A1RECQLAPP | |
| SCHEMBL31742565 | 0.91 | CHRNB2 (0.65) | CHRNB2CHRNA4ORAI1CYP3A4CHRNB4 | |
| SCHEMBL29469522 | 0.89 | CHRNB2 (0.62) | CHRNB2CHRNA4ALDH1A1RECQLKMT2A | |
| SCHEMBL238711 | 0.89 | CHRNB2 (0.62) | CHRNB2CHRNA4ALDH1A1RECQLKMT2A | |
| SCHEMBL4490297 | 0.84 | CHRNB2 (0.61) | CHRNB2CHRNA4KMT2ACYP3A4CHRNB4 | |
| SCHEMBL23596366 | 0.83 | CHRNB2 (0.60) | CHRNB2CHRNA4KMT2ACYP3A4 | |
| SCHEMBL20930335 | 0.83 | CHRNB2 (0.56) | CHRNB2CHRNA4ORAI1CYP3A4CHRNB4 | |
| SCHEMBL19875367 | 0.78 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL24343865 | 0.78 | APP (0.45) | CHRNB2CHRNA4ALDH1A1APPKMT2A | |
| SCHEMBL2009162 | 0.78 | APP (0.53) | ALDH1A1RECQLAPPKMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017210335-A1 | IMAGING METHODS USING 18F-RADIOLABELED BIOLOGICS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-07 | — | — | WO | disclosed |
| US-7960555-B2 | Substituted pyridine ligands and related water-soluble catalysts | UNIVERSITY OF MASSACHUSETTS (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090156767-A1 | Substituted pyridine ligands and related water-soluble catalysts | NAVY, SECRETARY OF THE UNITED STATES OF AMERICA | 2009-06-18 | — | — | US | disclosed |
| US-20080269444-A1 | PEG-Substituted Pyridine Ligands and Related Water-Soluble Catalysts | EMRICK TODD S | 2008-10-30 | — | — | US | disclosed |
| US-7332609-B2 | PEG-substituted pyridine ligands and related water-soluble catalysts | UNIVERSITY OF MASSACHUSETTS (US) | 2008-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156767-A1 | Substituted pyridine ligands and related water-soluble catalysts | MDM4, M6PR, PWWP2B | CHRNB2 3522/4885CHRNA4 2772/4885ALDH1A1 2123/4885 |
| US-20080269444-A1 | PEG-Substituted Pyridine Ligands and Related Water-Soluble Catalysts | PAM, EGFR, NAPEPLD | CHRNB2 4420/4885CHRNA4 3876/4885ALDH1A1 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.